Answers are grounded in this paper and cite their sources.
Future clinical trials emphasize dual cardiorenal endpoints to enhance patient outcomes and reduce disease burden.
Future clinical trials should adopt dual cardiorenal endpoints to better evaluate treatment effects. Combination therapies require rigorous investigation to establish optimal efficacy and safety profiles. These advances hold promise for optimizing multidisciplinary care, reducing disease burden, improving patient outcomes, and enhancing global health.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: